Catalyst Biosciences

Catalyst Biosciences company information, Employees & Contact Information

Updated May 2026

Quick answer

Catalyst Biosciences is a Biotechnology Research company. It has approximately 12 employees on record. Contact data was last refreshed in May 2026. Find Catalyst Biosciences's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.

Company Details

Employees
12
Address
611 Gateway Blvd, South San Francisco,ca 94080,united States
Phone
+1 650 871 0761
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, CA
Looking for a particular Catalyst Biosciences employee's phone or email?

Catalyst Biosciences Questions

News

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewswire

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 GlobeNewswire

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewswire

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors GlobeNewswire

Catalyst Biosciences Completes First Steps in Reverse Merger Plan - Yahoo Finance

Catalyst Biosciences Completes First Steps in Reverse Merger Plan Yahoo Finance

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - GlobeNewswire

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GlobeNewswire

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewswire

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China GlobeNewswire

Catalyst Biosciences Announces Completion of Business - GlobeNewswire

Catalyst Biosciences Announces Completion of Business GlobeNewswire

Catalyst Biosciences Announces Global License and - GlobeNewswire

Catalyst Biosciences Announces Global License and GlobeNewswire

Top Catalyst Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant